Clinical Trial Update: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 [Phase 2]

View source ↗

Summary

PROSEEK is a Phase 2 trial evaluating K0706, an Abl kinase inhibitor, for early Parkinson's disease; the study was terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• K0706

Snippet

Sponsor: Sun Pharma Advanced Research Company Limited | Conditions: Early Parkinson Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-07-25